CHPA on third class of drugs
This article was originally published in The Tan Sheet
Executive Summary
Two-class system of Rx and OTC drug regulation is a "time-tested system that provides consumers with convenient, cost-effective and safe treatment options," trade group maintains in 1May 27 statement reaffirming its opposition to "third class, or so-called transition class" of drugs. 2"The Tan Sheet" May 26, 2003 (p. 5) suggested CHPA was re-assessing its long-standing opposition to the idea of a third class...
You may also be interested in...
Behind-The-Counter Drug Class “On The Table” At CHPA
The Consumer Healthcare Products Association appears to have softened its steadfast opposition to a possible behind-the-counter third class of drugs
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.